RxDoctor Payments Data

Stephen Gallo, MD

Urology · Springfield, MANPI 1013076546

Payments from drug & device makers

$1,179in general payments, 2019–2025

Across 46 payments — averaging $25.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$217
  • Sumitomo Pharma America, Inc.$164
  • Bard Peripheral Vascular, Inc.$159
  • Olympus America Inc.$108
  • Ferring Pharmaceuticals Inc.$107
  • Urogen Pharma, Inc.$95
  • plus $330 from 10 others

What the payments were for

  • Food & beverage$1,179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,179 in reported general payments places this provider in the 40th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$646,857
Medicare patients
1,775
Services billed
11,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron31$35,657
MyrbetriqMirabegron32$21,163
Finasteride387$6,768
Tamsulosin Hcl392$6,683
Oxybutynin Chloride ErOxybutynin Chloride46$1,961
Solifenacin Succinate16$1,713
Alfuzosin Hcl ErAlfuzosin Hcl74$1,430
Tadalafil12$541
Dutasteride14$382
Terazosin Hcl15$340
Cephalexin26$202
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$188
Ciprofloxacin Hcl67$165
Oxybutynin Chloride11$129
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$164$35,65731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 327 urology providers in Massachusetts.

Other urology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →